^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    1d
    CELF2 is a tumor suppressor that modulates SLC7A11 and promotes ferroptosis in stomach adenocarcinoma. (PubMed, Mol Cancer Res)
    CELF2 is a tumor suppressor that promotes the level and susceptibility of ferroptosis in STAD cells by targeting SLC7A11. Implications: This study offers valuable molecular insights for the development of ferroptosis-targeted therapies for STAD.
    Journal
    |
    CELF2 (CUGBP Elav-Like Family Member 2) • SLC7A11 (Solute Carrier Family 7 Member 11)
    3d
    Analysis and validation of abnormal signaling pathways and immune cell infiltration characteristics in digestive system cancers based on peroxisome-related genes. (PubMed, Biol Direct)
    Peroxisomes act as pivotal regulators of digestive cancer progression by modulating signaling pathways, the TIME, therapeutic resistance, and lipid metabolism. Targeting peroxisomal function, particularly in high-risk subgroups of HCC and CRC, warrants further exploration as a promising therapeutic strategy.
    Journal
    |
    PEX13 (Peroxisomal Biogenesis Factor 13)
    |
    Lenvima (lenvatinib)
    6d
    HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies. (PubMed, Int J Mol Sci)
    A cross-tumor perspective contrasts GC/GEJ testing and biology with the breast cancer paradigm and summarizes the importance of HER2-low expression in non-gastric malignancies. Finally, we discuss the therapeutic strategies in HER2-low GC/GEJ and highlight key safety and monitoring considerations for HER2-directed ADCs.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 underexpression • HER-2 positive + HER-2 overexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Aidixi (disitamab vedotin)
    7d
    Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers (clinicaltrials.gov)
    P=N/A, N=100, Completed, West China Hospital | Recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    9d
    Galectin 3 expression in gastrointestinal tumors identified through comprehensive bioinformatic mapping. (PubMed, Discov Oncol)
    These findings suggest LGALS3 as a promising diagnostic and prognostic biomarker, and a potential therapeutic target to enhance immune responses in GI cancers.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • LGALS3 (Galectin 3) • MAPK3 (Mitogen-Activated Protein Kinase 3)
    9d
    Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704. (PubMed, Gastric Cancer)
    Preoperative DOS for gastric cancer with ELM yielded unprecedentedly favorable 3-year survival outcomes and was considered a provisional standard of care without a phase III trial within our JCOG community.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cisplatin • docetaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    9d
    RAGIP: Recurrence After Gastric and Intestinal Polyp Resection (clinicaltrials.gov)
    P=N/A, N=2000, Not yet recruiting, LanZhou University | Initiation date: Jan 2026 --> Jul 2026
    Trial initiation date
    10d
    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)
    P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)
    10d
    How to Define the Gastroesophageal Junction. (PubMed, Dig Endosc)
    Furthermore, we will briefly discuss endoscopic treatment, chemotherapy, and surgical treatment for GEJ cancer. Looking ahead, the reclassification of GEJ cancers using the Kyoto international consensus, coupled with comprehensive molecular analyses of tumors, promises to yield valuable insights.
    Review • Journal
    |
    CDX2 (Caudal Type Homeobox 2)
    10d
    Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=52, Recruiting, Qilu Hospital of Shandong University
    New trial • HEOR
    13d
    Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer (clinicaltrials.gov)
    P2, N=26, Completed, Samsung Medical Center | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)